Benign Prostatic Hyperplasia
An enlarged prostate is common and usually harmless — but 'just getting older' is not a diagnosis
What it is
Benign prostatic hyperplasia is a non-cancerous enlargement of the prostate gland that becomes steadily more common with age — present in roughly half of men in their fifties and sixties, and the great majority by their eighties. As the prostate grows it can squeeze the urethra it surrounds, producing the cluster of urinary symptoms doctors call lower urinary tract symptoms: a weak or hesitant stream, straining, a sense of not fully emptying, and — the one that wakes people up — needing to pass urine frequently, including at night. The word that matters most here is benign. BPH is not prostate cancer, does not become prostate cancer, and does not raise the risk of it; the two are different diseases that happen to share an organ and an age group.
Why it matters
Two things can go wrong with how this condition is understood, in opposite directions. The first is to over-worry: to read urinary symptoms as a sign of cancer. They usually are not — BPH arises in the inner (transition) zone of the prostate, while cancer typically arises in the outer (peripheral) zone, and symptom severity does not track cancer risk. The second, and the reason this page exists, is to under-worry: to wave the symptoms away as an inevitable part of ageing and miss the minority that are not benign at all. New or changing urinary symptoms can occasionally signal urinary retention, infection, bladder stones, kidney strain, or — separately — a prostate cancer that happens to coexist. 'Just your age' is a reassurance people are given too easily; the honest version is that it is usually benign and still worth assessing properly once.
What BioSignal knows about treating this
What works for Benign Prostatic Hyperplasia
BioSignal’s clinical summary, most important first.
- Watchful waiting with lifestyle measures — appropriate for mild or non-bothersome symptoms
- Alpha-blockers (tamsulosin, alfuzosin, doxazosin, silodosin) — fast symptom relief; they relax the prostate but do not shrink it
- 5-alpha-reductase inhibitors (finasteride, dutasteride) — shrink the prostate over months and reduce retention and surgery, best for larger glands
- Combination therapy (alpha-blocker plus 5-alpha-reductase inhibitor) — greater reduction in progression for men with larger prostates
- Tadalafil (a daily low-dose PDE5 inhibitor) — improves symptoms, useful where erectile dysfunction coexists
- Surgery (TURP as the reference standard; UroLift, Rezum and HoLEP among the alternatives) — for refractory symptoms or complications
New to this? Read these first
How this usually unfolds
- Recognize risk factors
- Get diagnosed
- Track key biomarkers
- Lifestyle first
- Evidence-based treatment
- Long-term monitoring
Who is at risk
- Increasing age — the dominant factor by far
- Family history of BPH
- Obesity, type 2 diabetes and the metabolic syndrome
- Physical inactivity
- Hormonal changes with age (BPH growth is driven by dihydrotestosterone, DHT)
How it's diagnosed
The diagnosis is clinical and is built from the symptom pattern rather than a single test. A validated questionnaire — the International Prostate Symptom Score (IPSS), based on the American Urological Association Symptom Index — quantifies severity and tracks change over time. Examination includes a digital rectal examination to gauge prostate size and feel for irregularity, a urine test to exclude infection and blood, and, where obstruction is suspected, measures of urine flow and post-void residual volume. PSA (prostate-specific antigen) may be measured, but its interpretation is the part people get wrong: BPH itself raises PSA because a bigger prostate makes more of it, so an elevated PSA is not specific for cancer and is not a test for BPH. Whether to check PSA at all is a shared decision about prostate-cancer screening — a separate question with its own trade-offs — not a routine part of diagnosing an enlarged prostate.
Key biomarkers
Lifestyle
Explore this condition across BioSignal
Related Foundations
Related body systems
Related conditions
Frequently asked questions
Does an enlarged prostate mean I have or will get prostate cancer?
No. This is the single most important thing to understand about BPH, and it is reassuring: benign prostatic hyperplasia is not cancer, does not turn into cancer, and does not increase your risk of prostate cancer. The two conditions even tend to start in different parts of the prostate — BPH in the inner zone around the urethra (which is why it affects urine flow), and cancer more often in the outer zone (which is why early cancer usually causes no urinary symptoms at all). They are common at the same ages, so a man can have both, but one does not cause the other. The strength of your urinary symptoms tells you about your BPH; it does not tell you about your cancer risk.
Does saw palmetto work for an enlarged prostate?
The best evidence says no. Saw palmetto is one of the most popular supplements sold for prostate symptoms, and it has been tested properly. In a rigorous US trial (CAMUS), men took saw palmetto at up to three times the usual dose for over a year, and it relieved symptoms no better than placebo — if anything the placebo did marginally better. A Cochrane review pooling 32 trials and more than 5,600 men reached the same conclusion: no improvement over placebo in urinary symptoms, urine flow, or prostate size. This is a case where the marketing and the evidence point in opposite directions, and BioSignal reports the evidence: for BPH, saw palmetto does not work.
Do the medications actually help, and which one?
They do, and the choice depends on your prostate and your priorities. Alpha-blockers (such as tamsulosin) work within days by relaxing the muscle in the prostate and bladder neck; they ease symptoms but do not shrink the gland or change the long-term course, and can cause dizziness and changes in ejaculation. 5-alpha-reductase inhibitors (finasteride, dutasteride) actually shrink the prostate over months and, in large trials, roughly halved the risk of acute urinary retention and of needing surgery — most useful when the prostate is genuinely enlarged, at the cost of a slower onset and possible sexual side effects. For larger prostates, combining the two reduces progression more than either alone. One practical trap worth knowing: 5-alpha-reductase inhibitors roughly halve PSA, so the measured value has to be doubled when interpreting it — otherwise a real rise can be masked.
When does an enlarged prostate need surgery?
Surgery is considered when symptoms are severe and not controlled by medication, or when complications appear: repeated urinary retention, recurrent urinary infections, bladder stones, blood in the urine coming from the prostate, or kidney strain from a bladder that cannot empty. The long-standing reference operation is TURP (transurethral resection of the prostate), and there is now a range of less invasive options — the prostatic urethral lift (UroLift), water-vapour therapy (Rezum), and laser enucleation (HoLEP) among them — chosen according to prostate size and individual circumstances. Surgery is effective, but it is a step taken for a clear reason, not a default; most men with BPH never need it.
I'm waking up several times a night to pee — is that just BPH?
Often it is, but not always, and it is worth being specific because the causes differ. In BPH, night-time waking (nocturia) comes from a combination of incomplete bladder emptying and an irritable bladder. But nocturia also has causes that have nothing to do with the prostate — drinking fluid late in the evening, heart or kidney conditions that shift fluid handling, poorly controlled diabetes, sleep apnoea, and certain medications. That is why the symptom is a reason to be assessed rather than to self-diagnose an enlarged prostate. If waking to pee comes with a weak stream and daytime symptoms, BPH is likely; if it comes alone, or with thirst, swelling, or breathlessness, the answer may lie elsewhere.
When should urinary symptoms be treated as urgent?
When you suddenly cannot pass urine at all despite a full, painful bladder — that is acute urinary retention, and it needs emergency care. Seek prompt assessment too for visible blood in the urine, a fever with urinary symptoms (which may mean infection reaching the kidney or prostate), or urinary symptoms alongside unexplained weight loss or bone pain. Blood in the urine in particular should never be attributed to BPH without being properly investigated — it is a red flag that must be looked into rather than assumed benign. Most enlarged-prostate symptoms are not emergencies, but these specific features are the exceptions that matter.
Evidence summary
Benign prostatic hyperplasia is a common, benign, age-related enlargement of the prostate that is distinct from prostate cancer and does not progress to it. Management is driven by how bothersome the symptoms are: mild symptoms warrant watchful waiting; alpha-blockers give rapid symptomatic relief without altering the disease course; 5-alpha-reductase inhibitors shrink the gland over months and, in landmark randomised trials (PLESS, MTOPS), roughly halved the risk of acute urinary retention and the need for surgery, with the greatest benefit in larger prostates and the practical caveat that they halve PSA. Combination therapy reduces clinical progression more than monotherapy in men with larger glands. Saw palmetto, the most popular supplement for the condition, was no better than placebo in a high-quality dose-escalation trial (CAMUS) and in a Cochrane review of 32 trials — a clear negative that its marketing does not reflect. PSA interpretation is a recurrent pitfall: BPH itself raises PSA, so an elevated value is not specific for cancer and PSA is not a diagnostic test for BPH; whether to screen for prostate cancer with PSA is a separate shared decision (USPSTF: individualised for ages 55-69, not recommended at 70 and over). Surgery, with TURP as the reference standard alongside newer minimally invasive options, is reserved for refractory symptoms or complications. This page addresses benign enlargement; prostate cancer is a distinct disease on which BioSignal has not published, and urinary red flags such as visible blood in the urine require investigation rather than reassurance.
References & sources
- Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984;132(3):474-479 (PMID 6206240)
- Barry MJ, Fowler FJ Jr, O'Leary MP, et al. The American Urological Association Symptom Index for Benign Prostatic Hyperplasia (reprint of the 1992 index). J Urol 2017;197(2S):S189-S197 (PMID 28012747)
- McConnell JD, Roehrborn CG, Bautista OM, et al. (MTOPS Research Group). The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349(25):2387-2398 (PMID 14681504)
- McConnell JD, Bruskewitz R, Walsh P, et al. (PLESS Study Group). The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 1998;338(9):557-563 (PMID 9475762)
- Roehrborn CG, Siami P, Barkin J, et al. (CombAT Study Group). The effects of dutasteride, tamsulosin and combination therapy on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 2010;57(1):123-131 (PMID 19825505)
- Chang DF, Campbell JR. Intraoperative floppy iris syndrome associated with tamsulosin. J Cataract Refract Surg 2005;31(4):664-673 (PMID 15899440)
- Porst H, Kim ED, Casabe AR, et al. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Eur Urol 2011;60(5):1105-1113 (PMID 21871706)
- Barry MJ, Meleth S, Lee JY, et al. (CAMUS Study Group). Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial. JAMA 2011;306(12):1344-1351 (PMID 21954478)
- Tacklind J, MacDonald R, Rutks I, Stanke JU, Wilt TJ. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev 2012;12:CD001423 (PMID 23235581)
- Sandhu JS, Bixler BR, Dahm P, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline amendment 2023. J Urol 2024 (PMID 37706750)
- US Preventive Services Task Force. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. JAMA 2018;319(18):1901-1913 (DOI 10.1001/jama.2018.3710)
Educational information — not medical advice
Is this condition page clear, accurate, and useful? Your feedback shapes what we review next.
Give feedback